1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, G.V. Long, V.G. Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Muhammad A. Khattak, M.S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, P. Lorigan, D. Grebennik, C. Krepler, Sandrine Marréaud, Stefan Suciu, C. Robert (2024). 1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.1163.